Abbvie acquires Cerevel Therapeutics
James Spargo | August 2, 2024 | News story | Mergers and Acquisitions | AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.
Cerevel has multiple programmes across neurological and psychiatric conditions such as schizophrenia, Parkinson’s disease and mood disorders. One example is emraclidine, a next-generation antipsychotic positive allosteric modulator (PAM) of the muscarinic M4 receptor, indicated for the treatment of schizophrenia. There is also tavapadon, a dopamine D1/D5 selective partial agonist for the management of Parkinson’s disease, which is currently in phase 3 studies.
Darigabat, an alpha 2/3/5 selective GABAA receptor PAM for the treatment-resistant epilepsy and panic disorder, is currently in phase 2, and CVL-354 – a kappa opioid receptor (KOR) antagonist currently in phase 1 – has the potential to provide improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD).
“Abbvie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond,” said Robert A Michael, chief executive officer, AbbVie. “Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie.”
James Spargo
2/8/24
Related Content
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
Esaote presents new MRI system to support brain glioma surgeries
Gliomas are among the most common primary malignant brain tumours
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo …
